Tagged with Oncology

Switzerland World-renowned oncologist Professor Susan Gasser outlines the innovative public-private partnership model in place at the ISREC Foundation at the AGORA Cancer Research Center in Lausanne. The unique model of ISREC/AGORA involves a reversal of the typical PPP structure, where the private foundation builds infrastructure and invites public institutions to collaborate,…

Global In conversation at ESMO 2024 in Barcelona, Astellas Chief Medical Officer Tadaaki Taniguchi lays out some of the company’s most promising recent oncology data, his hopes around how Astellas’ modality-based strategy will ultimately bring “meaningfully differentiated” therapies to patients, and why next-generation treatments stand to reshape the cancer care paradigm.…

Mexico Hernán Porcile, General Manager of Takeda Mexico, discusses the company’s innovative therapies, regulatory strategies, and the integration of ” “Takeda-ism” within the Mexican cultural context. He emphasizes Takeda’s commitment to sustainability, diversity, and collaboration with local healthcare ecosystems.   Respecting our legacy as a Japanese company while adapting to the…

France In conversation at ESMO 2024, Pierre Fabre’s R&D Head Francesco Hofmann outlines some of the key data readouts for the company’s oncology portfolio from this year’s conference, how it is looking to expand its R&D portfolio via business development deals and biotech partnerships, and the spaces in which a mid-sized…

Mexico Oswaldo Bernal explains how Mexico is BMS’ top-performing market in Latin America (outside of Brazil) and plays a significant role in the company’s global growth strategy. He also discusses how Mexican patients face hurdles in accessing new treatments due to low health investment and lengthy regulatory approval processes, as well…

Europe This year’s European Society of Medical Oncology (ESMO) was the largest ever. Over 33,000 people attended ESMO Congress 2024 at Barcelona’s cavernous Fira Gran Via conference centre, where 5,000 abstracts were presented and 600 expert speakers took to the stage. The healthcare professionals and cancer drug developers in attendance were…

China Yoshio Uchida, President of Daiichi Sankyo China, outlines the company’s strategic focus on Antibody-Drug Conjugates (ADCs) within China’s oncology market and China’s relevant role in the company’s global R&D operations. He explains how Daiichi Sankyo is addressing the challenges of a dynamic healthcare environment while emphasizing the company’s commitment to…

China Dr George Chen explores D3 Bio’s strategic approach to drug development, its ambition to launch two cancer therapies in the US within five years, and the critical role of partnerships and funding in achieving these goals. Reflecting on this journey, Dr. Chen emphasizes, “It’s a journey to realize a dream…

Hong Kong Prominent oncologist and chair of the clinical oncology department at the Chinese University of Hong Kong Professor Tony Mok comments on the potential  of the Antibody Drug Conjugates (ADC) platform and discusses boosting clinical trials in Hong Kong and the difficulties posed by a shortage of doctors in the territory.…

Hong Kong Dr Jeremy Teoh highlights the importance of Hong Kong’s role in global urology research, emphasizing collaborations with international institutions and the Greater Bay Area. Despite the challenges of Hong Kong’s smaller scale, its strategic position allows it to bridge Eastern and Western medical practices, elevating research standards globally. Dr Teoh…

China Despite an adverse funding panorama and looming geopolitical tensions, Chinese biotech is still thriving. Companies originating in China are advancing promising pipelines, going public, looking beyond China’s borders with a record 63 cross-region out-licensing deals in 2023, and attracting the attention of global pharma. Recent PharmaBoardroom interviewees weigh in on…

China We last spoke with Xueming Qian, CEO and co-founder of the biotech Transcenta in 2019. Since then, the company has seen some important milestones: listing on the Hong Kong Stock Exchange and advancing its first-line gastric cancer treatment into phase III trials. Qian outlines Transcenta’s progress, including its global multi-centre…